Dsicover a recent study that compared Stockholm3 with other established biomarkers for prostate cancer screening. Learn more.

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, ...

A biomarker, PROSTOX, predicted late genitourinary toxicity accurately in patients with prostate cancer, yielding an area under the curve of 0.76.

Several biomarker tests have been available for over a decade, with extensive research backing their effectiveness. Yet, many ...

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, UVA Cancer Center researchers have discovered.

It will also highlight the significance of exosomal mRNA and present two studies exploring the potential of exosomal mRNAs as a non-invasive biomarker for early prostate cancer screening.

According to Research by SNS Insider, Global Prostate Cancer Diagnostics Market Growth is Fueled by Growing Demand for Advanced Biomarker Testing, AI Diagnostics, and Outpatient Screening Services ...

Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharmaceutical company, issued a shareholder letter from CEO John Yu, M.D., outlining recen ...

in patients with prostate cancer HealthDay News — A biomarker consisting primarily of microRNA-based germline biomarkers (mirSNPs), PROSTOX, is valid for predicting radiotherapy (RT)-induced ...

Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the latest options here.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA® ...